Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kiniksa Pharmaceuticals reports robust Q2 growth and strategic initiatives

Kiniksa Pharmaceuticals delivered a strong Q2 performance with significant revenue growth driven by ARCALYST sales and strategic initiatives. The company's focus on disease awareness and patient base expansion bodes well for future growth.
While challenges such as managing expenses and addressing operational complexities persist, Kiniksa's solid financial position and market opportunities position it favorably for sustained growth and value creation.
Overall, Kiniksa Pharmaceuticals' Q2 earnings call highlights a mix of strong performance, strategic strengths, operational challenges, and growth opportunities, signaling a dynamic and evolving landscape for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman and Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Liisa Bayko - Evercore ISI Paul Choi - Goldman Sachs Eva Fortea-Verdejo - Wells Fargo David Nierengarten - Wedbush Securities Anupam Rama - JPMorgan Operator Good day and thank you for standing by. Welcome to Kiniksa Pharmaceuticals Third Quarter 2024 Earnings Conference Call.

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.01.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

– ARCALYST ® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY ® Award-winning singer-songwriter, Carly Pearce – – Kiniksa expects to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today –

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024 at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Makes Kiniksa Pharmaceuticals (KNSA) a Good Fit for 'Trend Investing'

The consensus price target hints at a 42.3% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet

Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Kiniksa Pharmaceuticals (KNSA) is on the Move, Here's Why the Trend Could be Sustainable

LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 8:00 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

The consensus price target hints at a 30.1% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade

AudioEye Inc

Balchem

Gorman-Rupp

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are KNSA, HNI, AEYE, BCPC, GRC.

5 Stocks With Recent Price Strength in a Volatile Market

Carvana

QCR Holdings

CVNA, QCRH, and KNSA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 1, 2024.

Best Momentum Stocks to Buy for August 1st

Kinross Gold

Micron Technology

Novocure

NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024.

New Strong Buy Stocks for August 1st

Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors?

Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know

Kiniksa Pharmaceuticals (KNSA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why

Kiniksa Pharmaceuticals surged after the company reported strong second quarter results and increased the full year net sales guidance range for Arcalyst. The strong performance is driven by increased demand following the recent sales force expansion. The improved outlook for Arcalyst warrants an increase in the valuation range.

Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q2 2024 Earnings Conference Call July 23, 2024 8:30 AM ET Company Participants Rachel Frank – Head of Investor Relations Sanj K. Patel – Chief Executive Officer Ross Moat – Chief Commercial Officer Mark Ragosa – Chief Financial Officer John Paolini – Chief Medical Officer Conference Call Participants Anupam Rama – JPMorgan Eva Fortea-Verdejo – Wells Fargo Liisa Bayko – Evercore ISI Operator Good day and thank you for standing by.

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates

– ARCALYST ® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $405 - $415 million – –  Abiprubart clinical development fully funded; Phase 2b clinical trial in Sjögren's Disease enrolling patients – – Kiniksa expects to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today –

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

– Abiprubart Phase 2b clinical trial in Sjögren's Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations –

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's Disease

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative activities and improve care quality – HAMILTON, Bermuda, June 17, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced its sponsorship of the American Heart Association's new Addressing Recurrent Pericarditis initiative, a multi-faceted effort to improve quality of care through identification, dissemination, and implementation of best practices for the diagnosis and management of recurrent pericarditis.

Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative

HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 8:40 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time).

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

Kiniksa Pharmaceuticals reported strong Q1 2024 results, with net sales of Arcalyst growing 85% YoY and 11% sequentially. Arcalyst's strong performance has driven a $10 million increase in the full-year net sales guidance range. Kiniksa plans to develop abiprubart for the treatment of Sjogren's syndrome, with a large phase 2b trial expected to start in the second half of the year.

Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA ) Q1 2024 Earnings Conference Call April 23, 2024 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Senior Vice President & Chief Commercial Officer John Paolini - Senior Vice President & Chief Medical Officer Mark Ragosa - Senior Vice President & Chief Financial Officer Eben Tessari - Chief Operating Officer Conference Call Participants Anupam Rama - JP Morgan Paul Choi - Goldman Sachs David Nierengarten - Wedbush Securities Geoff Meacham - Bank of America Operator Good day and thank you for standing by and welcome to Kiniksa Pharmaceuticals First Quarter 2024 Earnings Conference Call.

News for Kiniksa Pharmaceuticals Ltd Stock (KNSA)